首页|祛风止痉散在治疗支气管哮喘(哮病-风痰哮证)患者中对气道炎症及气道重塑的作用机制

祛风止痉散在治疗支气管哮喘(哮病-风痰哮证)患者中对气道炎症及气道重塑的作用机制

Effect of Qufeng Zhijing San on airway inflammation and airway remodelling in patients with bronchial asthma(asthma wind phlegm asthma syndrome)

扫码查看
目的 观察祛风止痉散对支气管哮喘(哮病风痰哮证)患者细胞外信号调节蛋白激酶1、2(Extracellular regulating kinase,ERK-1、ERK-2)、基质金属蛋白酶-9(Matrix metalloprotein-ase-9,MMP-9)、白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-8(Interleukin-8,IL-8)、白细胞介素-13(Interleukin-13,IL-13)、白细胞介素-17(Interleukin-17,IL-17)、白细胞介素-32(Interleukin-32,IL-32)、血清类黏蛋白1样蛋白3基因(Orosomucoid1-like protein3,ORMDL3)的影响,探讨祛风止痉散对改善哮喘气道炎症的作用机制.方法 选择2021年7月至2022年5月就诊于新疆维吾尔自治区中医医院确诊为支气管哮喘(哮病-风痰哮证)患者75例,按随机数字表法分为对照组(n=38)和作为试验组(n=37);同时选择同期健康体检者作为健康组(n=10).对照组给予布地奈德福莫特罗粉吸入剂(160/4.5μg),每日2次,每次1吸;试验组在对照组基础上联合中药祛风止痉散口服;疗程3个月.健康组不予治疗.分别采用聚合酶链反应(Polymerase chain reac-tion,PCR)、酶联免疫吸附法(Enzyme linked immunosorbent assay,ELISA)检测并比较3组用药前后ERK-1、ERK-2、ORMDL3、MMP-9、IL-6、IL-8、IL-13、IL-1 7、IL-32水平差异.结果 治疗前,与健康组比较,对照组、试验组ORMDL-3、ERK-2、ERK-1水平明显升高,差异有统计学意义(P<0.05);与健康组比较,对照组、试验组MMP-9表达水平差异无统计学意义(P>0.05);与对照组比较,试验组ORMDL-3、ERK-2、ERK-1、MMP-9表达水平差异均无统计学意义(P>0.05).治疗后,试验组与对照组IL-6、IL-8、IL-17、IL-32、ERK-1、ORMDL-3差异均无统计学意义(P>0.05),但试验组IL-13、ERK-2水平较对照组明显降低,差异有统计学意义(P<0.05).结论 祛风止痉散可能通过降低ERK-2和IL-13的表达水平,进而减轻支气管哮喘(哮病-风痰哮证)患者介导的炎症反应.
Objective Observing the effects of Qufeng Zhijing San on extracellular signal regulated pro-tein kinase-1,ERK-2,matrix metalloproteinase-9,IL-6,IL-8,and IL-13 in patients with bronchial asth-ma(asthma wind phlegm asthma syndrome).The effects of Interleukin-17(IL-17),Interleukin-32(IL-32)and serum Orosmucoid1-like protein 3(ORMDL3)genes on asthma airway inflammation were investi-gated,and the mechanism of Qufeng Zhijing San in improving asthma airway inflammation was explored.Methods 75 patients diagnosed with bronchial asthma(asthma wind phlegm asthma syndrome)who visi-ted to the hospital from July 2021 to May 2022 were randomly divided into a control group(n=38)and an experimental group(n=37)using a random number table method.Simultaneously select individuals who underwent health examinations during the same period as health group(n=10).The control group was given budesonide fumoterol powder inhaler(160/4.5μg)twice a day,with one inhaler per session.The experimental group was orally administered in combination with traditional Chinese medicine(TCM)Qufeng Zhijing San on the basis of the control group.The treatment period was 3 months.The health group will not receive treatment.Polymerase chain reaction(PCR)and enzyme-linked immunosorbent as-say(ELISA)were used to detect and compare the differences in ERK-1,ERK-2,ORMDL-3,MMP-9,IL-6,IL-8,IL-13,IL-17 and IL-32 levels among the 3 groups before and after the medication.Results Before the treatment,compared with the healthy group,the levels of ORMDL-3,ERK-2 and ERK-1 in the control group and experimental group were significantly increased,with statistical significance(P<0.05);Com-pared with the healthy group,there was no statistically significant difference in MMP-9 expression levels between control group and experimental group(P>0.05).Compared with control group,there was no statistically significant difference in the expression levels of ORMDL-3,ERK-2,ERK-1 and MMP-9 in the experimental group(P>0.05).After the treatment,there was no statistically significant difference be-tween experimental group and control group in IL-6,IL-8,IL-17,IL-32,ERK-1 and ORMDL-3(P>0.05),but the levels of IL-13 and ERK-2 in the experimental group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05).Conclusion Qufeng Zhijing San may alleviate the inflammatory response mediated by patients with bronchial asthma(asthma wind phlegm asthma syndrome)by reducing the expression level of ERK-2 and IL-13.

Qufeng Zhijing Sanbronchial asthmaextracellular regulating kinaseinterleukin

王玲、杨柳、展楠楠、姚龙龙、席磊

展开 >

新疆维吾尔自治区中医药研究院

新疆维吾尔自治区中医医院,乌鲁木齐 830000

新疆医科大学中医学院,乌鲁木齐 830017

祛风止痉散 支气管哮喘 细胞外信号调节蛋白激酶 白细胞介素

新疆维吾尔自治区自然科学基金面上项目

2021D01C216

2024

新疆医科大学学报
新疆医科大学

新疆医科大学学报

CSTPCD
影响因子:0.76
ISSN:1009-5551
年,卷(期):2024.47(1)
  • 31